Formulation of PEG-ylated L-asparaginase loaded poly (lactide-co-glycolide) nanoparticles: Influence of PEGylation on enzyme loading, activity and in vitro release

Pharmazie

Volumn 66, Issue 12, 2011, Pages 956-960

  Suri Vasudev, S ^a   Ahmad, Sayeed ^a   Parveen, R ^a   Ahmad, F J ^a   Anish, C K ^b   Ali, M ^a   Panda, A K ^b  

^a HAMDARD UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CONJUGATE; DRUG FORMULATION; EMULSION; ENCAPSULATION; ENZYME ACTIVITY; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; IN VITRO STUDY; ISOMER; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE; ULTRASOUND;

ASPARAGINASE; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EMULSIONS; LACTIC ACID; LYSINE; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR WEIGHT; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RHEOLOGY; SOLVENTS; ULTRASONICS;

EID: 84855678453     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1058     Document Type: Article

References (18)

1. Broome MBJD (1963) Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects: II. lymphoma 6C3HED cells cultured in a medium devoid of l-asparagine lose their susceptibility to the effects of guinea pig serum In Vivo. J Exp Med 118: 121-148.
2. Brown LR (2005) Commercial challenges of protein drug delivery. Exp Opin drug deliv 2: 29-42.
3. Crotts G, Sah H Park TG (1997) Adsorption determines in-vitro protein release rate from biodegradable microspheres: quantitative analysis of surface area during degradation. J Control Release 47: 101-111. (Pubitemid 27154405)
4. Diwan M Park TG (2001) Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Control Release 73: 233-244. (Pubitemid 32539252)
5. Frokjaer S Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4: 298-306. (Pubitemid 41130943)
6. Gaspar MM, Perez-Soler R Cruz MEM (1996) Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 38: 373-377.
7. Harris JM, Nancy E, Marlene M (2001) Pegylation: A novel process for modifying pharmacokinetics. Clin Pharma Cokin 40: 539-551.
8. Hindsa KD, Campbella KM, Hollanda KM, Lewis DW, Pichéa CA, Schmidta PG (2005) PEGylated insulin in PLGA microparticles: in vivo and in vitro analysis. J Control Release 104: 447-460.
9. Inada Y, Furukawa M, Sasaki H, Kodera Y, Hiroto M, Nishimura H, Matsushima A (1995) Biomedical and biotechnological applications of PEG and PM-modified proteins. Trends Biotechnol 13: 86-91.
10. Jorge JCS, Perez-Soler R, Morais JG, Cruz MEM (1994) Liposomal palmitoyl-L-asparaginase: characterization and biological activity. Cancer Chemother Pharmacol 34: 230-234. (Pubitemid 24178514)
11. Lu W, Park TG (1995), Protein release from poly(lactic-co-glycolic acid) microspheres: protein stability problems. PDA J Pharm Sci Technol 49: 9-13.
12. Mashburn L, Wriston J Jr (1964) Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 105: 451-452. (1967) Inhibition of leukemias in man by L-asparaginase. Cancer Res 27: 2619-2631.
13. Putney SD, Burke PA(1998) Improving protein therapeutics with sustainedrelease formulations. Nature Biotech 16: 153-157. (Pubitemid 128723585)
14. Qing-Long G, Min-Shu W, Zhen C (2002) Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo. Acta Pharmacol Sin 23: 946-951.
15. Sah H (1999) Protein behavior at the water/methylene chloride interface. J Pharm Sci 88: 1320-1325.
16. Swain AL, Lski MJ, Houssett D, Mohana Rao JK and Wlodawert A (1993) Crystal structure of Escherichia coli l-asparaginase and enzyme used in cancer therapy. Proc Natl Acad Sci USA 90: 1474-1478. (Pubitemid 23058195)
17. Wang W (1999) Instability, stabilization and formulation of liquid protein pharmaceuticals. Int J Pharm 185: 129-188.
18. Weert M, Hennink WE Jiskoot W (2000) Protein instability in poly (lacticco- glycolic acid) microparticles. Pharm Res 17: 1159-1167.